GlycoMimetics shares crash after Pfizer team dismisses their lead drug as a PhIII failure
Close to 8 years ago, the BD team at Pfizer signed a $340 million deal to license in a mid-stage drug from GlycoMimetics for a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
